Kisspeptin Dosage Guide: Fertility Protocols, Testosterone Support, and Timing

Kisspeptin is a naturally occurring neuropeptide encoded by the KISS1 gene — a hypothalamic master regulator of the reproductive axis. Often called the "gatekeeper of puberty," Kisspeptin is the primary upstream activator of GnRH (gonadotropin-releasing hormone) neurons in the hypothalamus. When Kisspeptin binds its receptor (KISS1R, formerly GPR54), it triggers GnRH release, which in turn stimulates LH (luteinizing hormone) and FSH (follicle-stimulating hormone) secretion from the pituitary, ultimately driving gonadal sex steroid production — testosterone in men, estrogen and progesterone in women.

This central position in reproductive neuroendocrinology makes Kisspeptin one of the most pharmacologically significant peptides in fertility medicine and a growing area of interest in male hormone optimization.

Kisspeptin Isoforms: Which One Are You Using?

Kisspeptin exists in several biologically active forms derived from the same KISS1 gene product through proteolytic cleavage:

• Kisspeptin-54 (KP-54): The full-length endogenous form; longest duration of action
• Kisspeptin-14 (KP-14): Intermediate isoform
• Kisspeptin-10 (KP-10): The shortest active fragment; most commonly used in research and peptide therapy due to lower molecular weight, easier synthesis, and retained potency at KISS1R

Kisspeptin-10 is the standard form in research peptide markets and in most published human studies. Unless otherwise specified, dosing references in this guide apply to Kisspeptin-10.

How Kisspeptin Works in the Hormonal Axis

Understanding Kisspeptin's position in the HPG (hypothalamic-pituitary-gonadal) axis is essential for using it appropriately:

Kisspeptin neurons in the hypothalamus (specifically the arcuate nucleus and anteroventral periventricular nucleus) receive signals from gonadal steroids, energy status, stress hormones, and circadian cues. They integrate this information and release Kisspeptin to regulate GnRH pulsatility.

When exogenous Kisspeptin is administered:

1. Kisspeptin binds KISS1R on GnRH neurons
2. GnRH is released into the pituitary portal circulation
3. GnRH stimulates LH and FSH secretion from the anterior pituitary
4. LH acts on Leydig cells (in men) to produce testosterone; FSH drives sperm production

This cascade makes Kisspeptin a particularly elegant approach to testosterone support — it works at the hypothalamic level rather than bypassing the HPG axis entirely (as exogenous testosterone does) or acting at the pituitary level (as HCG does).

Research-Based Dosing

Kisspeptin dosing protocols are derived from clinical research primarily in reproductive endocrinology settings:

Acute LH/Testosterone Stimulation

• Dose: 1–10 nmol/kg body weight (intravenous in research settings)
• Converted to practical subQ dosing: approximately 50–100 mcg per injection for a 70–80 kg individual
• This dose range produces reliable LH pulses in human research

Subcutaneous Research Protocol (Testosterone Support)

• Dose: 50–100 mcg subcutaneous per injection
• Frequency: Once to twice daily, or pulsatile dosing to mimic natural kisspeptin rhythms (see Timing section)
• Duration: 4–8 week cycles with off-cycle periods

Fertility-Stimulating Protocol (Higher Dose)

Research in hypogonadotropic hypogonadism (HH) and infertility uses continuous infusion or frequent pulsatile injection protocols:

• KP-54 continuous infusion: 0.1–3.2 nmol/kg/hour IV (clinical research only)
• KP-10 pulsatile subQ: 100 mcg every 90 minutes (impractical for most users; insulin pump delivery systems have been investigated)
• Practical fertility protocol: 100 mcg subQ twice daily for 4–6 weeks before planned conception; this approximates pulsatile stimulation while remaining practical

Timing Strategies

Timing is more important for Kisspeptin than for most peptides because its effects are tightly coupled to the natural pulsatility of the HPG axis.

Key timing principles:

Pulsatile delivery matters: Kisspeptin's endogenous action is pulsatile, not continuous. Continuous exposure to high Kisspeptin levels leads to KISS1R desensitization and paradoxical suppression of GnRH secretion. This is the same principle underlying the difference between pulsatile GnRH (which stimulates the pituitary) and continuous GnRH agonists like leuprolide (which suppress it). For testosterone support, twice-daily injections are generally preferable to single large daily doses.

Morning alignment: Natural testosterone peaks in the early morning (6–8 AM), driven by overnight LH pulsatility. A morning Kisspeptin injection (6–8 AM, fasted or 2 hours after a light meal) aligns with natural hormonal rhythms and may produce better testosterone support than afternoon dosing.

Pre-sleep dose: An optional pre-bed dose (10 PM–midnight) can support overnight LH pulsatility, though this is a less established practice.

Avoiding interference from high testosterone: Kisspeptin neurons are sensitive to negative feedback from testosterone and estradiol. At physiologically elevated testosterone levels, KISS1R signaling is partially suppressed. This is the natural feedback loop — and it means Kisspeptin is most effective in individuals with suppressed or low-normal testosterone rather than those with already-elevated testosterone.

Kisspeptin for Male Testosterone Support

The primary male hormone optimization application for Kisspeptin is secondary hypogonadism — low testosterone caused by inadequate LH/FSH signaling rather than primary testicular failure. In this context, Kisspeptin addresses the root cause (inadequate hypothalamic GnRH drive) rather than simply replacing testosterone.

Clinical evidence: Published human studies demonstrate that IV and subQ Kisspeptin administration in men with hypogonadotropic hypogonadism produces significant LH and testosterone increases. A study published in the Journal of Clinical Endocrinology & Metabolism showed a 2–4 fold increase in LH within 60 minutes of Kisspeptin administration, with testosterone rising over 4–8 hours.

Advantages over TRT (testosterone replacement therapy):

• Maintains HPG axis activity and testicular function (no testicular atrophy)
• Preserves fertility (LH and FSH both stimulated)
• Avoids exogenous testosterone's suppressive effects on endogenous production
• May be more physiologically sustainable long-term for men with functional (reversible) hypogonadism

Post-cycle therapy (PCT) application: Kisspeptin has potential as a PCT tool after anabolic steroid cycles, where suppressed GnRH drive requires stimulation for recovery. Combining Kisspeptin with traditional PCT agents (Clomid, Nolvadex) addresses the recovery from the hypothalamic level down, potentially improving recovery speed. This application is research-informed but not yet clinically validated.

Kisspeptin in Female Fertility Protocols

Kisspeptin has been studied in women for ovulation induction as an alternative to hCG (human chorionic gonadotropin) for triggering ovulation in IVF protocols. This application is the most clinically advanced Kisspeptin application:

IVF ovulation trigger: KP-54 administered as a single IV dose (9.6 nmol/kg) triggers the LH surge needed for final oocyte maturation in IVF. Clinical trials showed this approach significantly reduces ovarian hyperstimulation syndrome (OHSS) risk compared to hCG, which is a major safety concern in high-response IVF patients.

Practical female fertility protocol (research context, not clinical practice):

• 100 mcg KP-10 subQ, twice daily for 4–8 weeks
• Times with natural menstrual phase (follicular phase preferred)
• Use with reproductive endocrinologist oversight only

KISS1 Gene and Fertility Conditions

Loss-of-function mutations in KISS1 or KISS1R cause normosmic hypogonadotropic hypogonadism (nHH) — a condition where individuals have normal olfaction but fail to enter puberty due to absent GnRH drive. Research into Kisspeptin began largely as a result of studying these genetic cases, and it remains the most validated application of Kisspeptin therapy.

Conversely, KISS1 gain-of-function mutations cause precocious puberty — premature activation of the reproductive axis. The clinical utility of Kisspeptin antagonists is now being explored for precocious puberty management.

Side Effects and Considerations

Kisspeptin is generally well-tolerated in research settings. Reported effects include:

• Mild injection site reactions: Standard subQ injection discomfort; generally minimal
• Transient flushing: Some research subjects report brief facial flushing following KP administration, correlating with the LH surge
• Libido changes: Increased libido is commonly reported, consistent with acute testosterone elevation
• Nausea: Rare, reported in some IV infusion studies at higher doses; less common with subQ use
• Desensitization with continuous dosing: As noted, continuous high-dose Kisspeptin exposure leads to KISS1R downregulation. Pulsatile dosing is essential to avoid paradoxical suppression.

Kisspeptin is contraindicated in hormone-sensitive cancers (prostate cancer, certain breast cancers) where stimulating the testosterone/estrogen axis is contraindicated.

Frequently Asked Questions

Q: Is Kisspeptin better than HCG for testosterone support? They act at different levels of the HPG axis. HCG directly stimulates LH receptors on the testes, bypassing the pituitary. Kisspeptin works at the hypothalamic level, maintaining more natural pulsatility of the entire axis including FSH (which HCG does not stimulate effectively). For fertility preservation, Kisspeptin may be preferable. For direct testosterone support, HCG has more clinical data.

Q: Can Kisspeptin be used with TRT? This combination is somewhat contradictory — TRT suppresses the HPG axis via negative feedback on hypothalamic Kisspeptin neurons, which would blunt Kisspeptin's effects. If the goal is maintaining testicular function during TRT, HCG is more directly effective. Kisspeptin is most useful when trying to stimulate endogenous testosterone without exogenous androgens.

Q: How long does a Kisspeptin injection take to raise LH? In human research, LH begins rising within 15–30 minutes of subQ Kisspeptin administration, peaks at approximately 60 minutes, and returns toward baseline by 2–4 hours. Testosterone rises more slowly, peaking 4–8 hours post-injection.

Q: What should I monitor while using Kisspeptin? Key labs: total testosterone, free testosterone, LH, FSH, and estradiol at baseline and every 4–6 weeks during a protocol. This allows dose adjustment based on actual hormonal response rather than subjective effects alone.

Q: Is Kisspeptin legal? In the United States, Kisspeptin is not FDA-approved for any indication and is classified as a research chemical. It is legal to purchase for research purposes. In fertility medicine, KP-54 has been used in clinical trials under IND applications.